• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Sionna Therapeutics, Inc. - Common Stock (NQ:SION)

    35.84 -1.33 (-3.58%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Sionna Therapeutics, Inc. - Common Stock

    News headline image
    Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics to Participate in Upcoming December Investor Conferences
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics Reports Third Quarter 2025 Financial Results
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics to Participate in Upcoming November Investor Conferences
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics Reports Second Quarter 2025 Financial Results
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics Reports First Quarter 2025 Financial Results
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Sionna Therapeutics, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.